Global Autoimmune Drugs Market

Autoimmune Drugs Comprehensive Study by Type (B cell inhibitors, T cell inhibitors, Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Immunosuppressants, Beta Interferons, Insulin, Others), Application (Hospital, Clinical Laboratories), Mechanism of Action (TNF inhibitors, IL blockers, COX inhibitors, Phosphodiestrase Type 4 inhibitors), Disease Type (Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Psoriasis, Inflammatory Bowel Disease (IBD), Ankylosing Spondylitis (AS), Systemic Lupus Erythematosus (SLE)), Drug Class (DMARDs, NSAIDs, Corticosteroids, Analgesics, Immunosuppresants) Players and Region - Global Market Outlook to 2028

Autoimmune Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
According to National Institute of Health, approximately 50 million population in the United States are suffering from autoimmune diseases. The diseases in estimated to be one of the top 10 cause of death in women under the age 65, and it is the second highest cause of chronic illness. Also, it is the top cause of morbidity in women in the United States. There are more than 80 clinically different type of autoimmune diseases identified till date. Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body leads to autoimmune diseases.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories (United States), Active Biotech AB (Sweden), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States), Zydus Cadila (India), Autoimmune Technologies (United States) and Bristol-Myers Squibb (United States)


This growth is primarily driven by High Cost of Autoimmune Drugs due to the initiatives taken by the Government to reduce the cost therapies of autoimmune disorders like rheumatoid arthritis, Increased prevalence of autoimmune diseases and Introduction of affordable Biosimilars and its advanced treatment option for patients with autoimmune disorders..

Globally, a noticeable market trend is evident Owing to a huge patient pool and developing healthcare technology is expected to propel the market growth rate. The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott Laboratories (United States), Active Biotech AB (Sweden), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States), Zydus Cadila (India), Autoimmune Technologies (United States) and Bristol-Myers Squibb (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market appears to be highly competitive due to the presence of many market players who are offering multiple treatment options for Autoimmune disease. Apart from the high cost of the drugs, the complex treatment of autoimmune diseases and a severe lack of effective diagnostic, these factors are challenging the market. The competitive environment is expected to increase due to the product extensions, new products, and new applications of the products and services provided.

Key Developments in the Market:
In November 2018, The Food and Drug Administration approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.
In February 2019, Calliditas Therapeutics AB announced the Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Autoimmune hepatitis (AIH). This confirms the high unmet medical need and further encourages us to continue to explore orphan indications in which we could leverage our existing expertise.

Influencing Trend:
Owing to a huge patient pool and developing healthcare technology is expected to propel the market growth rate.

Market Growth Drivers:
High Cost of Autoimmune Drugs due to the initiatives taken by the Government to reduce the cost therapies of autoimmune disorders like rheumatoid arthritis, Increased prevalence of autoimmune diseases and Introduction of affordable Biosimilars and its advanced treatment option for patients with autoimmune disorders.

Challenges:
Insurers are reluctant to provide reimbursement for the drugs for the treatment of autoimmune diseases due to lack of knowledge.

Restraints:
Patent expiry of the drugs used for autoimmune disease and poor healthcare system in underdeveloped countries and Despite the efforts made by the Government, autoimmune drugs remains expensive, this may hamper the market growth

Opportunities:
Factors such as the targeted therapeutic mechanism of biologics and the high cost of autoimmune drugs will provide considerable growth opportunities to autoimmune drugs manufactures of this market

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Autoimmune Drugs Market
- Analysis about New Entrants in Autoimmune Drugs Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Autoimmune Drugs Study Sheds Light on
— The Autoimmune Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Autoimmune Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Autoimmune Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • B cell inhibitors
  • T cell inhibitors
  • Tumor Necrosis Factor Inhibitors
  • Interleukin Inhibitors
  • Immunosuppressants
  • Beta Interferons
  • Insulin
  • Others
By Application
  • Hospital
  • Clinical Laboratories
By Mechanism of Action
  • TNF inhibitors
  • IL blockers
  • COX inhibitors
  • Phosphodiestrase Type 4 inhibitors

By Disease Type
  • Rheumatoid Arthritis (RA)
  • Multiple Sclerosis (MS)
  • Psoriasis
  • Inflammatory Bowel Disease (IBD)
  • Ankylosing Spondylitis (AS)
  • Systemic Lupus Erythematosus (SLE)

By Drug Class
  • DMARDs
  • NSAIDs
  • Corticosteroids
  • Analgesics
  • Immunosuppresants

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Cost of Autoimmune Drugs due to the initiatives taken by the Government to reduce the cost therapies of autoimmune disorders like rheumatoid arthritis
      • 3.2.2. Increased prevalence of autoimmune diseases
      • 3.2.3. Introduction of affordable Biosimilars and its advanced treatment option for patients with autoimmune disorders.
    • 3.3. Market Challenges
      • 3.3.1. Insurers are reluctant to provide reimbursement for the drugs for the treatment of autoimmune diseases due to lack of knowledge.
    • 3.4. Market Trends
      • 3.4.1. Owing to a huge patient pool and developing healthcare technology is expected to propel the market growth rate.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Autoimmune Drugs, by Type, Application, Mechanism of Action, Disease Type, Drug Class and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Autoimmune Drugs (Value)
      • 5.2.1. Global Autoimmune Drugs by: Type (Value)
        • 5.2.1.1. B cell inhibitors
        • 5.2.1.2. T cell inhibitors
        • 5.2.1.3. Tumor Necrosis Factor Inhibitors
        • 5.2.1.4. Interleukin Inhibitors
        • 5.2.1.5. Immunosuppressants
        • 5.2.1.6. Beta Interferons
        • 5.2.1.7. Insulin
        • 5.2.1.8. Others
      • 5.2.2. Global Autoimmune Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinical Laboratories
      • 5.2.3. Global Autoimmune Drugs by: Mechanism of Action (Value)
        • 5.2.3.1. TNF inhibitors
        • 5.2.3.2. IL blockers
        • 5.2.3.3. COX inhibitors
        • 5.2.3.4. Phosphodiestrase Type 4 inhibitors
      • 5.2.4. Global Autoimmune Drugs by: Disease Type (Value)
        • 5.2.4.1. Rheumatoid Arthritis (RA)
        • 5.2.4.2. Multiple Sclerosis (MS)
        • 5.2.4.3. Psoriasis
        • 5.2.4.4. Inflammatory Bowel Disease (IBD)
        • 5.2.4.5. Ankylosing Spondylitis (AS)
        • 5.2.4.6. Systemic Lupus Erythematosus (SLE)
      • 5.2.5. Global Autoimmune Drugs by: Drug Class (Value)
        • 5.2.5.1. DMARDs
        • 5.2.5.2. NSAIDs
        • 5.2.5.3. Corticosteroids
        • 5.2.5.4. Analgesics
        • 5.2.5.5. Immunosuppresants
      • 5.2.6. Global Autoimmune Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Autoimmune Drugs (Volume)
      • 5.3.1. Global Autoimmune Drugs by: Type (Volume)
        • 5.3.1.1. B cell inhibitors
        • 5.3.1.2. T cell inhibitors
        • 5.3.1.3. Tumor Necrosis Factor Inhibitors
        • 5.3.1.4. Interleukin Inhibitors
        • 5.3.1.5. Immunosuppressants
        • 5.3.1.6. Beta Interferons
        • 5.3.1.7. Insulin
        • 5.3.1.8. Others
      • 5.3.2. Global Autoimmune Drugs by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinical Laboratories
      • 5.3.3. Global Autoimmune Drugs by: Mechanism of Action (Volume)
        • 5.3.3.1. TNF inhibitors
        • 5.3.3.2. IL blockers
        • 5.3.3.3. COX inhibitors
        • 5.3.3.4. Phosphodiestrase Type 4 inhibitors
      • 5.3.4. Global Autoimmune Drugs by: Disease Type (Volume)
        • 5.3.4.1. Rheumatoid Arthritis (RA)
        • 5.3.4.2. Multiple Sclerosis (MS)
        • 5.3.4.3. Psoriasis
        • 5.3.4.4. Inflammatory Bowel Disease (IBD)
        • 5.3.4.5. Ankylosing Spondylitis (AS)
        • 5.3.4.6. Systemic Lupus Erythematosus (SLE)
      • 5.3.5. Global Autoimmune Drugs by: Drug Class (Volume)
        • 5.3.5.1. DMARDs
        • 5.3.5.2. NSAIDs
        • 5.3.5.3. Corticosteroids
        • 5.3.5.4. Analgesics
        • 5.3.5.5. Immunosuppresants
      • 5.3.6. Global Autoimmune Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Autoimmune Drugs (Price)
      • 5.4.1. Global Autoimmune Drugs by: Type (Price)
  • 6. Autoimmune Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Active Biotech AB (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Zydus Cadila (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Autoimmune Technologies (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Autoimmune Drugs Sale, by Type, Application, Mechanism of Action, Disease Type, Drug Class and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Autoimmune Drugs (Value)
      • 7.2.1. Global Autoimmune Drugs by: Type (Value)
        • 7.2.1.1. B cell inhibitors
        • 7.2.1.2. T cell inhibitors
        • 7.2.1.3. Tumor Necrosis Factor Inhibitors
        • 7.2.1.4. Interleukin Inhibitors
        • 7.2.1.5. Immunosuppressants
        • 7.2.1.6. Beta Interferons
        • 7.2.1.7. Insulin
        • 7.2.1.8. Others
      • 7.2.2. Global Autoimmune Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinical Laboratories
      • 7.2.3. Global Autoimmune Drugs by: Mechanism of Action (Value)
        • 7.2.3.1. TNF inhibitors
        • 7.2.3.2. IL blockers
        • 7.2.3.3. COX inhibitors
        • 7.2.3.4. Phosphodiestrase Type 4 inhibitors
      • 7.2.4. Global Autoimmune Drugs by: Disease Type (Value)
        • 7.2.4.1. Rheumatoid Arthritis (RA)
        • 7.2.4.2. Multiple Sclerosis (MS)
        • 7.2.4.3. Psoriasis
        • 7.2.4.4. Inflammatory Bowel Disease (IBD)
        • 7.2.4.5. Ankylosing Spondylitis (AS)
        • 7.2.4.6. Systemic Lupus Erythematosus (SLE)
      • 7.2.5. Global Autoimmune Drugs by: Drug Class (Value)
        • 7.2.5.1. DMARDs
        • 7.2.5.2. NSAIDs
        • 7.2.5.3. Corticosteroids
        • 7.2.5.4. Analgesics
        • 7.2.5.5. Immunosuppresants
      • 7.2.6. Global Autoimmune Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Autoimmune Drugs (Volume)
      • 7.3.1. Global Autoimmune Drugs by: Type (Volume)
        • 7.3.1.1. B cell inhibitors
        • 7.3.1.2. T cell inhibitors
        • 7.3.1.3. Tumor Necrosis Factor Inhibitors
        • 7.3.1.4. Interleukin Inhibitors
        • 7.3.1.5. Immunosuppressants
        • 7.3.1.6. Beta Interferons
        • 7.3.1.7. Insulin
        • 7.3.1.8. Others
      • 7.3.2. Global Autoimmune Drugs by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinical Laboratories
      • 7.3.3. Global Autoimmune Drugs by: Mechanism of Action (Volume)
        • 7.3.3.1. TNF inhibitors
        • 7.3.3.2. IL blockers
        • 7.3.3.3. COX inhibitors
        • 7.3.3.4. Phosphodiestrase Type 4 inhibitors
      • 7.3.4. Global Autoimmune Drugs by: Disease Type (Volume)
        • 7.3.4.1. Rheumatoid Arthritis (RA)
        • 7.3.4.2. Multiple Sclerosis (MS)
        • 7.3.4.3. Psoriasis
        • 7.3.4.4. Inflammatory Bowel Disease (IBD)
        • 7.3.4.5. Ankylosing Spondylitis (AS)
        • 7.3.4.6. Systemic Lupus Erythematosus (SLE)
      • 7.3.5. Global Autoimmune Drugs by: Drug Class (Volume)
        • 7.3.5.1. DMARDs
        • 7.3.5.2. NSAIDs
        • 7.3.5.3. Corticosteroids
        • 7.3.5.4. Analgesics
        • 7.3.5.5. Immunosuppresants
      • 7.3.6. Global Autoimmune Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Autoimmune Drugs (Price)
      • 7.4.1. Global Autoimmune Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Autoimmune Drugs: by Type(USD Million)
  • Table 2. Autoimmune Drugs B cell inhibitors , by Region USD Million (2017-2022)
  • Table 3. Autoimmune Drugs T cell inhibitors , by Region USD Million (2017-2022)
  • Table 4. Autoimmune Drugs Tumor Necrosis Factor Inhibitors , by Region USD Million (2017-2022)
  • Table 5. Autoimmune Drugs Interleukin Inhibitors , by Region USD Million (2017-2022)
  • Table 6. Autoimmune Drugs Immunosuppressants , by Region USD Million (2017-2022)
  • Table 7. Autoimmune Drugs Beta Interferons , by Region USD Million (2017-2022)
  • Table 8. Autoimmune Drugs Insulin , by Region USD Million (2017-2022)
  • Table 9. Autoimmune Drugs Others , by Region USD Million (2017-2022)
  • Table 10. Autoimmune Drugs: by Application(USD Million)
  • Table 11. Autoimmune Drugs Hospital , by Region USD Million (2017-2022)
  • Table 12. Autoimmune Drugs Clinical Laboratories , by Region USD Million (2017-2022)
  • Table 13. Autoimmune Drugs: by Mechanism of Action(USD Million)
  • Table 14. Autoimmune Drugs TNF inhibitors , by Region USD Million (2017-2022)
  • Table 15. Autoimmune Drugs IL blockers , by Region USD Million (2017-2022)
  • Table 16. Autoimmune Drugs COX inhibitors , by Region USD Million (2017-2022)
  • Table 17. Autoimmune Drugs Phosphodiestrase Type 4 inhibitors , by Region USD Million (2017-2022)
  • Table 18. Autoimmune Drugs: by Disease Type(USD Million)
  • Table 19. Autoimmune Drugs Rheumatoid Arthritis (RA) , by Region USD Million (2017-2022)
  • Table 20. Autoimmune Drugs Multiple Sclerosis (MS) , by Region USD Million (2017-2022)
  • Table 21. Autoimmune Drugs Psoriasis , by Region USD Million (2017-2022)
  • Table 22. Autoimmune Drugs Inflammatory Bowel Disease (IBD) , by Region USD Million (2017-2022)
  • Table 23. Autoimmune Drugs Ankylosing Spondylitis (AS) , by Region USD Million (2017-2022)
  • Table 24. Autoimmune Drugs Systemic Lupus Erythematosus (SLE) , by Region USD Million (2017-2022)
  • Table 25. Autoimmune Drugs: by Drug Class(USD Million)
  • Table 26. Autoimmune Drugs DMARDs , by Region USD Million (2017-2022)
  • Table 27. Autoimmune Drugs NSAIDs , by Region USD Million (2017-2022)
  • Table 28. Autoimmune Drugs Corticosteroids , by Region USD Million (2017-2022)
  • Table 29. Autoimmune Drugs Analgesics , by Region USD Million (2017-2022)
  • Table 30. Autoimmune Drugs Immunosuppresants , by Region USD Million (2017-2022)
  • Table 31. South America Autoimmune Drugs, by Country USD Million (2017-2022)
  • Table 32. South America Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 33. South America Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 34. South America Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 35. South America Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 36. South America Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 37. Brazil Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 38. Brazil Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 39. Brazil Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 40. Brazil Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 41. Brazil Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 42. Argentina Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 43. Argentina Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 44. Argentina Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 45. Argentina Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 46. Argentina Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 47. Rest of South America Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 48. Rest of South America Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 49. Rest of South America Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 50. Rest of South America Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 51. Rest of South America Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 52. Asia Pacific Autoimmune Drugs, by Country USD Million (2017-2022)
  • Table 53. Asia Pacific Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 54. Asia Pacific Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 55. Asia Pacific Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 56. Asia Pacific Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 57. Asia Pacific Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 58. China Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 59. China Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 60. China Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 61. China Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 62. China Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 63. Japan Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 64. Japan Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 65. Japan Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 66. Japan Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 67. Japan Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 68. India Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 69. India Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 70. India Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 71. India Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 72. India Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 73. South Korea Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 74. South Korea Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 75. South Korea Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 76. South Korea Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 77. South Korea Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 78. Taiwan Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 79. Taiwan Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 80. Taiwan Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 81. Taiwan Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 82. Taiwan Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 83. Australia Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 84. Australia Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 85. Australia Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 86. Australia Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 87. Australia Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 88. Rest of Asia-Pacific Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 89. Rest of Asia-Pacific Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 90. Rest of Asia-Pacific Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 91. Rest of Asia-Pacific Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 92. Rest of Asia-Pacific Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 93. Europe Autoimmune Drugs, by Country USD Million (2017-2022)
  • Table 94. Europe Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 95. Europe Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 96. Europe Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 97. Europe Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 98. Europe Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 99. Germany Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 100. Germany Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 101. Germany Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 102. Germany Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 103. Germany Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 104. France Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 105. France Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 106. France Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 107. France Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 108. France Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 109. Italy Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 110. Italy Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 111. Italy Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 112. Italy Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 113. Italy Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 114. United Kingdom Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 115. United Kingdom Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 116. United Kingdom Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 117. United Kingdom Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 118. United Kingdom Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 119. Netherlands Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 120. Netherlands Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 121. Netherlands Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 122. Netherlands Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 123. Netherlands Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 124. Rest of Europe Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 125. Rest of Europe Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 126. Rest of Europe Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 127. Rest of Europe Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 128. Rest of Europe Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 129. MEA Autoimmune Drugs, by Country USD Million (2017-2022)
  • Table 130. MEA Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 131. MEA Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 132. MEA Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 133. MEA Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 134. MEA Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 135. Middle East Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 136. Middle East Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 137. Middle East Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 138. Middle East Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 139. Middle East Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 140. Africa Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 141. Africa Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 142. Africa Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 143. Africa Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 144. Africa Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 145. North America Autoimmune Drugs, by Country USD Million (2017-2022)
  • Table 146. North America Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 147. North America Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 148. North America Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 149. North America Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 150. North America Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 151. United States Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 152. United States Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 153. United States Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 154. United States Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 155. United States Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 156. Canada Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 157. Canada Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 158. Canada Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 159. Canada Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 160. Canada Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 161. Mexico Autoimmune Drugs, by Type USD Million (2017-2022)
  • Table 162. Mexico Autoimmune Drugs, by Application USD Million (2017-2022)
  • Table 163. Mexico Autoimmune Drugs, by Mechanism of Action USD Million (2017-2022)
  • Table 164. Mexico Autoimmune Drugs, by Disease Type USD Million (2017-2022)
  • Table 165. Mexico Autoimmune Drugs, by Drug Class USD Million (2017-2022)
  • Table 166. Autoimmune Drugs Sales: by Type(Tons)
  • Table 167. Autoimmune Drugs Sales B cell inhibitors , by Region Tons (2017-2022)
  • Table 168. Autoimmune Drugs Sales T cell inhibitors , by Region Tons (2017-2022)
  • Table 169. Autoimmune Drugs Sales Tumor Necrosis Factor Inhibitors , by Region Tons (2017-2022)
  • Table 170. Autoimmune Drugs Sales Interleukin Inhibitors , by Region Tons (2017-2022)
  • Table 171. Autoimmune Drugs Sales Immunosuppressants , by Region Tons (2017-2022)
  • Table 172. Autoimmune Drugs Sales Beta Interferons , by Region Tons (2017-2022)
  • Table 173. Autoimmune Drugs Sales Insulin , by Region Tons (2017-2022)
  • Table 174. Autoimmune Drugs Sales Others , by Region Tons (2017-2022)
  • Table 175. Autoimmune Drugs Sales: by Application(Tons)
  • Table 176. Autoimmune Drugs Sales Hospital , by Region Tons (2017-2022)
  • Table 177. Autoimmune Drugs Sales Clinical Laboratories , by Region Tons (2017-2022)
  • Table 178. Autoimmune Drugs Sales: by Mechanism of Action(Tons)
  • Table 179. Autoimmune Drugs Sales TNF inhibitors , by Region Tons (2017-2022)
  • Table 180. Autoimmune Drugs Sales IL blockers , by Region Tons (2017-2022)
  • Table 181. Autoimmune Drugs Sales COX inhibitors , by Region Tons (2017-2022)
  • Table 182. Autoimmune Drugs Sales Phosphodiestrase Type 4 inhibitors , by Region Tons (2017-2022)
  • Table 183. Autoimmune Drugs Sales: by Disease Type(Tons)
  • Table 184. Autoimmune Drugs Sales Rheumatoid Arthritis (RA) , by Region Tons (2017-2022)
  • Table 185. Autoimmune Drugs Sales Multiple Sclerosis (MS) , by Region Tons (2017-2022)
  • Table 186. Autoimmune Drugs Sales Psoriasis , by Region Tons (2017-2022)
  • Table 187. Autoimmune Drugs Sales Inflammatory Bowel Disease (IBD) , by Region Tons (2017-2022)
  • Table 188. Autoimmune Drugs Sales Ankylosing Spondylitis (AS) , by Region Tons (2017-2022)
  • Table 189. Autoimmune Drugs Sales Systemic Lupus Erythematosus (SLE) , by Region Tons (2017-2022)
  • Table 190. Autoimmune Drugs Sales: by Drug Class(Tons)
  • Table 191. Autoimmune Drugs Sales DMARDs , by Region Tons (2017-2022)
  • Table 192. Autoimmune Drugs Sales NSAIDs , by Region Tons (2017-2022)
  • Table 193. Autoimmune Drugs Sales Corticosteroids , by Region Tons (2017-2022)
  • Table 194. Autoimmune Drugs Sales Analgesics , by Region Tons (2017-2022)
  • Table 195. Autoimmune Drugs Sales Immunosuppresants , by Region Tons (2017-2022)
  • Table 196. South America Autoimmune Drugs Sales, by Country Tons (2017-2022)
  • Table 197. South America Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 198. South America Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 199. South America Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 200. South America Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 201. South America Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 202. Brazil Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 203. Brazil Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 204. Brazil Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 205. Brazil Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 206. Brazil Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 207. Argentina Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 208. Argentina Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 209. Argentina Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 210. Argentina Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 211. Argentina Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 212. Rest of South America Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 213. Rest of South America Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 214. Rest of South America Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 215. Rest of South America Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 216. Rest of South America Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 217. Asia Pacific Autoimmune Drugs Sales, by Country Tons (2017-2022)
  • Table 218. Asia Pacific Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 219. Asia Pacific Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 220. Asia Pacific Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 221. Asia Pacific Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 222. Asia Pacific Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 223. China Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 224. China Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 225. China Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 226. China Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 227. China Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 228. Japan Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 229. Japan Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 230. Japan Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 231. Japan Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 232. Japan Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 233. India Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 234. India Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 235. India Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 236. India Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 237. India Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 238. South Korea Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 239. South Korea Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 240. South Korea Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 241. South Korea Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 242. South Korea Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 243. Taiwan Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 244. Taiwan Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 245. Taiwan Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 246. Taiwan Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 247. Taiwan Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 248. Australia Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 249. Australia Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 250. Australia Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 251. Australia Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 252. Australia Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 253. Rest of Asia-Pacific Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 254. Rest of Asia-Pacific Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 255. Rest of Asia-Pacific Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 256. Rest of Asia-Pacific Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 257. Rest of Asia-Pacific Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 258. Europe Autoimmune Drugs Sales, by Country Tons (2017-2022)
  • Table 259. Europe Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 260. Europe Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 261. Europe Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 262. Europe Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 263. Europe Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 264. Germany Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 265. Germany Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 266. Germany Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 267. Germany Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 268. Germany Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 269. France Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 270. France Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 271. France Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 272. France Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 273. France Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 274. Italy Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 275. Italy Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 276. Italy Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 277. Italy Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 278. Italy Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 279. United Kingdom Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 280. United Kingdom Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 281. United Kingdom Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 282. United Kingdom Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 283. United Kingdom Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 284. Netherlands Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 285. Netherlands Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 286. Netherlands Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 287. Netherlands Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 288. Netherlands Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 289. Rest of Europe Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 290. Rest of Europe Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 291. Rest of Europe Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 292. Rest of Europe Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 293. Rest of Europe Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 294. MEA Autoimmune Drugs Sales, by Country Tons (2017-2022)
  • Table 295. MEA Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 296. MEA Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 297. MEA Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 298. MEA Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 299. MEA Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 300. Middle East Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 301. Middle East Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 302. Middle East Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 303. Middle East Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 304. Middle East Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 305. Africa Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 306. Africa Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 307. Africa Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 308. Africa Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 309. Africa Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 310. North America Autoimmune Drugs Sales, by Country Tons (2017-2022)
  • Table 311. North America Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 312. North America Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 313. North America Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 314. North America Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 315. North America Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 316. United States Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 317. United States Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 318. United States Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 319. United States Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 320. United States Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 321. Canada Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 322. Canada Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 323. Canada Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 324. Canada Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 325. Canada Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 326. Mexico Autoimmune Drugs Sales, by Type Tons (2017-2022)
  • Table 327. Mexico Autoimmune Drugs Sales, by Application Tons (2017-2022)
  • Table 328. Mexico Autoimmune Drugs Sales, by Mechanism of Action Tons (2017-2022)
  • Table 329. Mexico Autoimmune Drugs Sales, by Disease Type Tons (2017-2022)
  • Table 330. Mexico Autoimmune Drugs Sales, by Drug Class Tons (2017-2022)
  • Table 331. Autoimmune Drugs: by Type(USD/Units)
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Company Basic Information, Sales Area and Its Competitors
  • Table 337. Company Basic Information, Sales Area and Its Competitors
  • Table 338. Company Basic Information, Sales Area and Its Competitors
  • Table 339. Company Basic Information, Sales Area and Its Competitors
  • Table 340. Autoimmune Drugs: by Type(USD Million)
  • Table 341. Autoimmune Drugs B cell inhibitors , by Region USD Million (2023-2028)
  • Table 342. Autoimmune Drugs T cell inhibitors , by Region USD Million (2023-2028)
  • Table 343. Autoimmune Drugs Tumor Necrosis Factor Inhibitors , by Region USD Million (2023-2028)
  • Table 344. Autoimmune Drugs Interleukin Inhibitors , by Region USD Million (2023-2028)
  • Table 345. Autoimmune Drugs Immunosuppressants , by Region USD Million (2023-2028)
  • Table 346. Autoimmune Drugs Beta Interferons , by Region USD Million (2023-2028)
  • Table 347. Autoimmune Drugs Insulin , by Region USD Million (2023-2028)
  • Table 348. Autoimmune Drugs Others , by Region USD Million (2023-2028)
  • Table 349. Autoimmune Drugs: by Application(USD Million)
  • Table 350. Autoimmune Drugs Hospital , by Region USD Million (2023-2028)
  • Table 351. Autoimmune Drugs Clinical Laboratories , by Region USD Million (2023-2028)
  • Table 352. Autoimmune Drugs: by Mechanism of Action(USD Million)
  • Table 353. Autoimmune Drugs TNF inhibitors , by Region USD Million (2023-2028)
  • Table 354. Autoimmune Drugs IL blockers , by Region USD Million (2023-2028)
  • Table 355. Autoimmune Drugs COX inhibitors , by Region USD Million (2023-2028)
  • Table 356. Autoimmune Drugs Phosphodiestrase Type 4 inhibitors , by Region USD Million (2023-2028)
  • Table 357. Autoimmune Drugs: by Disease Type(USD Million)
  • Table 358. Autoimmune Drugs Rheumatoid Arthritis (RA) , by Region USD Million (2023-2028)
  • Table 359. Autoimmune Drugs Multiple Sclerosis (MS) , by Region USD Million (2023-2028)
  • Table 360. Autoimmune Drugs Psoriasis , by Region USD Million (2023-2028)
  • Table 361. Autoimmune Drugs Inflammatory Bowel Disease (IBD) , by Region USD Million (2023-2028)
  • Table 362. Autoimmune Drugs Ankylosing Spondylitis (AS) , by Region USD Million (2023-2028)
  • Table 363. Autoimmune Drugs Systemic Lupus Erythematosus (SLE) , by Region USD Million (2023-2028)
  • Table 364. Autoimmune Drugs: by Drug Class(USD Million)
  • Table 365. Autoimmune Drugs DMARDs , by Region USD Million (2023-2028)
  • Table 366. Autoimmune Drugs NSAIDs , by Region USD Million (2023-2028)
  • Table 367. Autoimmune Drugs Corticosteroids , by Region USD Million (2023-2028)
  • Table 368. Autoimmune Drugs Analgesics , by Region USD Million (2023-2028)
  • Table 369. Autoimmune Drugs Immunosuppresants , by Region USD Million (2023-2028)
  • Table 370. South America Autoimmune Drugs, by Country USD Million (2023-2028)
  • Table 371. South America Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 372. South America Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 373. South America Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 374. South America Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 375. South America Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 376. Brazil Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 377. Brazil Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 378. Brazil Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 379. Brazil Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 380. Brazil Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 381. Argentina Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 382. Argentina Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 383. Argentina Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 384. Argentina Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 385. Argentina Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 386. Rest of South America Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 387. Rest of South America Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 388. Rest of South America Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 389. Rest of South America Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 390. Rest of South America Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 391. Asia Pacific Autoimmune Drugs, by Country USD Million (2023-2028)
  • Table 392. Asia Pacific Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 393. Asia Pacific Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 394. Asia Pacific Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 395. Asia Pacific Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 396. Asia Pacific Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 397. China Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 398. China Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 399. China Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 400. China Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 401. China Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 402. Japan Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 403. Japan Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 404. Japan Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 405. Japan Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 406. Japan Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 407. India Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 408. India Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 409. India Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 410. India Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 411. India Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 412. South Korea Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 413. South Korea Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 414. South Korea Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 415. South Korea Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 416. South Korea Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 417. Taiwan Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 418. Taiwan Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 419. Taiwan Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 420. Taiwan Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 421. Taiwan Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 422. Australia Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 423. Australia Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 424. Australia Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 425. Australia Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 426. Australia Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 427. Rest of Asia-Pacific Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 428. Rest of Asia-Pacific Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 429. Rest of Asia-Pacific Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 430. Rest of Asia-Pacific Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 431. Rest of Asia-Pacific Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 432. Europe Autoimmune Drugs, by Country USD Million (2023-2028)
  • Table 433. Europe Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 434. Europe Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 435. Europe Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 436. Europe Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 437. Europe Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 438. Germany Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 439. Germany Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 440. Germany Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 441. Germany Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 442. Germany Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 443. France Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 444. France Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 445. France Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 446. France Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 447. France Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 448. Italy Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 449. Italy Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 450. Italy Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 451. Italy Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 452. Italy Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 453. United Kingdom Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 454. United Kingdom Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 455. United Kingdom Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 456. United Kingdom Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 457. United Kingdom Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 458. Netherlands Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 459. Netherlands Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 460. Netherlands Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 461. Netherlands Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 462. Netherlands Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 463. Rest of Europe Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 464. Rest of Europe Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 465. Rest of Europe Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 466. Rest of Europe Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 467. Rest of Europe Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 468. MEA Autoimmune Drugs, by Country USD Million (2023-2028)
  • Table 469. MEA Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 470. MEA Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 471. MEA Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 472. MEA Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 473. MEA Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 474. Middle East Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 475. Middle East Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 476. Middle East Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 477. Middle East Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 478. Middle East Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 479. Africa Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 480. Africa Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 481. Africa Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 482. Africa Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 483. Africa Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 484. North America Autoimmune Drugs, by Country USD Million (2023-2028)
  • Table 485. North America Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 486. North America Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 487. North America Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 488. North America Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 489. North America Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 490. United States Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 491. United States Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 492. United States Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 493. United States Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 494. United States Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 495. Canada Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 496. Canada Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 497. Canada Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 498. Canada Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 499. Canada Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 500. Mexico Autoimmune Drugs, by Type USD Million (2023-2028)
  • Table 501. Mexico Autoimmune Drugs, by Application USD Million (2023-2028)
  • Table 502. Mexico Autoimmune Drugs, by Mechanism of Action USD Million (2023-2028)
  • Table 503. Mexico Autoimmune Drugs, by Disease Type USD Million (2023-2028)
  • Table 504. Mexico Autoimmune Drugs, by Drug Class USD Million (2023-2028)
  • Table 505. Autoimmune Drugs Sales: by Type(Tons)
  • Table 506. Autoimmune Drugs Sales B cell inhibitors , by Region Tons (2023-2028)
  • Table 507. Autoimmune Drugs Sales T cell inhibitors , by Region Tons (2023-2028)
  • Table 508. Autoimmune Drugs Sales Tumor Necrosis Factor Inhibitors , by Region Tons (2023-2028)
  • Table 509. Autoimmune Drugs Sales Interleukin Inhibitors , by Region Tons (2023-2028)
  • Table 510. Autoimmune Drugs Sales Immunosuppressants , by Region Tons (2023-2028)
  • Table 511. Autoimmune Drugs Sales Beta Interferons , by Region Tons (2023-2028)
  • Table 512. Autoimmune Drugs Sales Insulin , by Region Tons (2023-2028)
  • Table 513. Autoimmune Drugs Sales Others , by Region Tons (2023-2028)
  • Table 514. Autoimmune Drugs Sales: by Application(Tons)
  • Table 515. Autoimmune Drugs Sales Hospital , by Region Tons (2023-2028)
  • Table 516. Autoimmune Drugs Sales Clinical Laboratories , by Region Tons (2023-2028)
  • Table 517. Autoimmune Drugs Sales: by Mechanism of Action(Tons)
  • Table 518. Autoimmune Drugs Sales TNF inhibitors , by Region Tons (2023-2028)
  • Table 519. Autoimmune Drugs Sales IL blockers , by Region Tons (2023-2028)
  • Table 520. Autoimmune Drugs Sales COX inhibitors , by Region Tons (2023-2028)
  • Table 521. Autoimmune Drugs Sales Phosphodiestrase Type 4 inhibitors , by Region Tons (2023-2028)
  • Table 522. Autoimmune Drugs Sales: by Disease Type(Tons)
  • Table 523. Autoimmune Drugs Sales Rheumatoid Arthritis (RA) , by Region Tons (2023-2028)
  • Table 524. Autoimmune Drugs Sales Multiple Sclerosis (MS) , by Region Tons (2023-2028)
  • Table 525. Autoimmune Drugs Sales Psoriasis , by Region Tons (2023-2028)
  • Table 526. Autoimmune Drugs Sales Inflammatory Bowel Disease (IBD) , by Region Tons (2023-2028)
  • Table 527. Autoimmune Drugs Sales Ankylosing Spondylitis (AS) , by Region Tons (2023-2028)
  • Table 528. Autoimmune Drugs Sales Systemic Lupus Erythematosus (SLE) , by Region Tons (2023-2028)
  • Table 529. Autoimmune Drugs Sales: by Drug Class(Tons)
  • Table 530. Autoimmune Drugs Sales DMARDs , by Region Tons (2023-2028)
  • Table 531. Autoimmune Drugs Sales NSAIDs , by Region Tons (2023-2028)
  • Table 532. Autoimmune Drugs Sales Corticosteroids , by Region Tons (2023-2028)
  • Table 533. Autoimmune Drugs Sales Analgesics , by Region Tons (2023-2028)
  • Table 534. Autoimmune Drugs Sales Immunosuppresants , by Region Tons (2023-2028)
  • Table 535. South America Autoimmune Drugs Sales, by Country Tons (2023-2028)
  • Table 536. South America Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 537. South America Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 538. South America Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 539. South America Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 540. South America Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 541. Brazil Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 542. Brazil Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 543. Brazil Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 544. Brazil Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 545. Brazil Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 546. Argentina Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 547. Argentina Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 548. Argentina Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 549. Argentina Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 550. Argentina Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 551. Rest of South America Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 552. Rest of South America Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 553. Rest of South America Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 554. Rest of South America Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 555. Rest of South America Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 556. Asia Pacific Autoimmune Drugs Sales, by Country Tons (2023-2028)
  • Table 557. Asia Pacific Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 558. Asia Pacific Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 559. Asia Pacific Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 560. Asia Pacific Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 561. Asia Pacific Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 562. China Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 563. China Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 564. China Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 565. China Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 566. China Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 567. Japan Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 568. Japan Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 569. Japan Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 570. Japan Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 571. Japan Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 572. India Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 573. India Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 574. India Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 575. India Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 576. India Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 577. South Korea Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 578. South Korea Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 579. South Korea Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 580. South Korea Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 581. South Korea Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 582. Taiwan Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 583. Taiwan Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 584. Taiwan Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 585. Taiwan Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 586. Taiwan Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 587. Australia Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 588. Australia Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 589. Australia Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 590. Australia Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 591. Australia Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 592. Rest of Asia-Pacific Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 593. Rest of Asia-Pacific Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 594. Rest of Asia-Pacific Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 595. Rest of Asia-Pacific Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 596. Rest of Asia-Pacific Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 597. Europe Autoimmune Drugs Sales, by Country Tons (2023-2028)
  • Table 598. Europe Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 599. Europe Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 600. Europe Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 601. Europe Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 602. Europe Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 603. Germany Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 604. Germany Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 605. Germany Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 606. Germany Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 607. Germany Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 608. France Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 609. France Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 610. France Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 611. France Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 612. France Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 613. Italy Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 614. Italy Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 615. Italy Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 616. Italy Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 617. Italy Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 618. United Kingdom Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 619. United Kingdom Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 620. United Kingdom Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 621. United Kingdom Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 622. United Kingdom Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 623. Netherlands Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 624. Netherlands Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 625. Netherlands Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 626. Netherlands Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 627. Netherlands Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 628. Rest of Europe Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 629. Rest of Europe Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 630. Rest of Europe Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 631. Rest of Europe Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 632. Rest of Europe Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 633. MEA Autoimmune Drugs Sales, by Country Tons (2023-2028)
  • Table 634. MEA Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 635. MEA Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 636. MEA Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 637. MEA Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 638. MEA Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 639. Middle East Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 640. Middle East Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 641. Middle East Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 642. Middle East Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 643. Middle East Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 644. Africa Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 645. Africa Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 646. Africa Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 647. Africa Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 648. Africa Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 649. North America Autoimmune Drugs Sales, by Country Tons (2023-2028)
  • Table 650. North America Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 651. North America Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 652. North America Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 653. North America Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 654. North America Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 655. United States Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 656. United States Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 657. United States Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 658. United States Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 659. United States Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 660. Canada Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 661. Canada Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 662. Canada Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 663. Canada Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 664. Canada Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 665. Mexico Autoimmune Drugs Sales, by Type Tons (2023-2028)
  • Table 666. Mexico Autoimmune Drugs Sales, by Application Tons (2023-2028)
  • Table 667. Mexico Autoimmune Drugs Sales, by Mechanism of Action Tons (2023-2028)
  • Table 668. Mexico Autoimmune Drugs Sales, by Disease Type Tons (2023-2028)
  • Table 669. Mexico Autoimmune Drugs Sales, by Drug Class Tons (2023-2028)
  • Table 670. Autoimmune Drugs: by Type(USD/Units)
  • Table 671. Research Programs/Design for This Report
  • Table 672. Key Data Information from Secondary Sources
  • Table 673. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Autoimmune Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Autoimmune Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Autoimmune Drugs: by Mechanism of Action USD Million (2017-2022)
  • Figure 7. Global Autoimmune Drugs: by Disease Type USD Million (2017-2022)
  • Figure 8. Global Autoimmune Drugs: by Drug Class USD Million (2017-2022)
  • Figure 9. South America Autoimmune Drugs Share (%), by Country
  • Figure 10. Asia Pacific Autoimmune Drugs Share (%), by Country
  • Figure 11. Europe Autoimmune Drugs Share (%), by Country
  • Figure 12. MEA Autoimmune Drugs Share (%), by Country
  • Figure 13. North America Autoimmune Drugs Share (%), by Country
  • Figure 14. Global Autoimmune Drugs: by Type Tons (2017-2022)
  • Figure 15. Global Autoimmune Drugs: by Application Tons (2017-2022)
  • Figure 16. Global Autoimmune Drugs: by Mechanism of Action Tons (2017-2022)
  • Figure 17. Global Autoimmune Drugs: by Disease Type Tons (2017-2022)
  • Figure 18. Global Autoimmune Drugs: by Drug Class Tons (2017-2022)
  • Figure 19. South America Autoimmune Drugs Share (%), by Country
  • Figure 20. Asia Pacific Autoimmune Drugs Share (%), by Country
  • Figure 21. Europe Autoimmune Drugs Share (%), by Country
  • Figure 22. MEA Autoimmune Drugs Share (%), by Country
  • Figure 23. North America Autoimmune Drugs Share (%), by Country
  • Figure 24. Global Autoimmune Drugs: by Type USD/Units (2017-2022)
  • Figure 25. Global Autoimmune Drugs share by Players 2022 (%)
  • Figure 26. Global Autoimmune Drugs share by Players (Top 3) 2022(%)
  • Figure 27. Global Autoimmune Drugs share by Players (Top 5) 2022(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 31. Active Biotech AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 32. Active Biotech AB (Sweden) Revenue: by Geography 2022
  • Figure 33. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 35. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 37. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 39. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 40. Zydus Cadila (India) Revenue: by Geography 2022
  • Figure 41. Autoimmune Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 42. Autoimmune Technologies (United States) Revenue: by Geography 2022
  • Figure 43. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 44. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 45. Global Autoimmune Drugs: by Type USD Million (2023-2028)
  • Figure 46. Global Autoimmune Drugs: by Application USD Million (2023-2028)
  • Figure 47. Global Autoimmune Drugs: by Mechanism of Action USD Million (2023-2028)
  • Figure 48. Global Autoimmune Drugs: by Disease Type USD Million (2023-2028)
  • Figure 49. Global Autoimmune Drugs: by Drug Class USD Million (2023-2028)
  • Figure 50. South America Autoimmune Drugs Share (%), by Country
  • Figure 51. Asia Pacific Autoimmune Drugs Share (%), by Country
  • Figure 52. Europe Autoimmune Drugs Share (%), by Country
  • Figure 53. MEA Autoimmune Drugs Share (%), by Country
  • Figure 54. North America Autoimmune Drugs Share (%), by Country
  • Figure 55. Global Autoimmune Drugs: by Type Tons (2023-2028)
  • Figure 56. Global Autoimmune Drugs: by Application Tons (2023-2028)
  • Figure 57. Global Autoimmune Drugs: by Mechanism of Action Tons (2023-2028)
  • Figure 58. Global Autoimmune Drugs: by Disease Type Tons (2023-2028)
  • Figure 59. Global Autoimmune Drugs: by Drug Class Tons (2023-2028)
  • Figure 60. South America Autoimmune Drugs Share (%), by Country
  • Figure 61. Asia Pacific Autoimmune Drugs Share (%), by Country
  • Figure 62. Europe Autoimmune Drugs Share (%), by Country
  • Figure 63. MEA Autoimmune Drugs Share (%), by Country
  • Figure 64. North America Autoimmune Drugs Share (%), by Country
  • Figure 65. Global Autoimmune Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Active Biotech AB (Sweden)
  • AstraZeneca plc (United Kingdom)
  • GlaxoSmithKline plc (United Kingdom)
  • Eli Lilly and Company (United States)
  • Zydus Cadila (India)
  • Autoimmune Technologies (United States)
  • Bristol-Myers Squibb (United States)
Additional players considered in the study are as follows:
AutoImmune Inc.(United States) , Johnson & Johnson Ltd. (India) , Lupin Pharmaceuticals Ltd. (India)
Select User Access Type

Key Highlights of Report


May 2023 214 Pages 53 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Autoimmune Drugs Market Quantitative research analysis
Global Autoimmune Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Autoimmune Drugs market are Abbott Laboratories (United States), Active Biotech AB (Sweden), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States), Zydus Cadila (India), Autoimmune Technologies (United States) and Bristol-Myers Squibb (United States), to name a few.
North America is dominating the Autoimmune Drugs Market.
"Insurers are reluctant to provide reimbursement for the drugs for the treatment of autoimmune diseases due to lack of knowledge." is seen as one of the major challenges by many Industry Players of Autoimmune Drugs Market
The Autoimmune Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Autoimmune Drugs market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Autoimmune Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Video Cystoscopes Comprehensive Study by Type (Flexible Cystoscopy, Rigid Cystoscopy), Application (Hospitals, Ambulatory Surgical Centers, Others), Length (37 cm, 40 cm), Cystoscopes Ranges (14 F, 1...
$ 3800
Oral Antiplatelets Comprehensive Study by Type (Irreversible Cyclooxygenase Inhibitors , ADP Receptor Inhibitors , Phosphodiesterase Inhibitors), Application (Acute Coronary Syndrome, Post Percutaneo...
$ 3750
Genitourinary Drugs Comprehensive Study by Type (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives), Drug Type (Hormonal Therapy, Targeted Drugs, Urinary Antispasmodics, Uterine relaxants...
$ 3750
Grass Pollen Allergy Drug Comprehensive Study by Type (BM-32, Pollinex Quattro Grass, Others), Application (Home Use, Hospital, Research Center) Players and Region - Global Market Outlook to 2027
$ 3500
Amlodipine Besylater Comprehensive Study by Type (2.5mg, 5mg, 10mg), Application (High Blood Pressure, Heart Disease), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies...
$ 3650
Mouth Ulcers Drugs Comprehensive Study by Type (Corticosteroid , Anesthetic , Analgesic , Antihistamine , Antimicrobial), Application (Adults, Kids), Indication Type (Aphthous Stomatitis, Oral Lichen...
$ 3650